Generic semaglutide has arrived in Canada
Health Canada has approved two generic semaglutide products as of May 2026, with seven additional submissions under review. Here's where the approval process stands today, what it means for pharmacy prices, and what's specifically excluded.
Approval timeline
Based on publicly available Health Canada filings and regulatory timelines.
October 30, 2025
Dr. Reddy’s Laboratories received a Notice of Non-Compliance from Health Canada on its initial generic semaglutide submission (resolved — see April 28, 2026).
December 22, 2025
Health Canada approved Plosbrio and Poviztra, Novo Nordisk’s lower-cost authorized brands of Ozempic and Wegovy respectively, ahead of the expected generic wave.
January 4, 2026
Novo Nordisk’s semaglutide data exclusivity expired in Canada, opening the regulatory pathway for generic manufacturers.
January 2026
Seven generic semaglutide submissions under Health Canada review from Sandoz Canada, Apotex (three submissions), Taro Pharmaceuticals, Aspen Pharmacare, and Teva Canada.
February 2, 2026
PharmaTher announced a strategic initiative to pursue Health Canada approval for generic semaglutide, targeting broad dose coverage from 0.25 mg to 2.4 mg.
April 28, 2026
Dr. Reddy’s Laboratories approved — first generic semaglutide approved by Health Canada. Type 2 diabetes indication only (equivalent to generic Ozempic). Dr. Reddy’s resolved its October 2025 Notice of Non-Compliance in approximately six months.
May 1, 2026
Apotex approved — Health Canada approved Apo-Semaglutide Injection, the second generic semaglutide product authorized in Canada. Type 2 diabetes indication only.
Through 2026
Additional generic semaglutide submissions remain under Health Canada review. Decisions expected throughout the year; manufacturer production scale-up and pharmacy availability typically lag approval by weeks to months.
Timeline is based on public information only. GLP1Prices does not have advance knowledge of Health Canada decisions.
What the price drop will actually look like
Canada's generic drug pricing framework — the pan-Canadian Tiered Pricing Framework, administered through the pan-Canadian Pharmaceutical Alliance — caps generic prices in steps as more manufacturers enter a market, with an automatic step-down built in even at the single-generic stage.
Using the current manufacturer list price for Ozempic of approximately $228 for a four-week supply (the official “brand reference price,” before pharmacy and distributor markups), the framework caps generic prices as follows:
| Stage | Generic price cap | Reduction from brand list |
|---|---|---|
| 1 generic, first 3 months | 75% of brand (~$171) | ~25% off |
| 1 generic, after 3 months | 55% of brand (~$125) | ~45% off |
| 2 generics | 50% of brand (~$114) | ~50% off |
| 3 or more generics (injectables) | 35% of brand (~$80) | ~65% off |
These are list-price caps for public drug plan formularies. Retail prices include pharmacy dispensing fees and markups, so absolute dollar figures at the counter will be higher than the table — but percentage reductions track proportionally.
With two manufacturers approved in May 2026 and pharmacy price comparison showing launches just beginning, the realistic near-term consumer price reduction lands in the 25–50% range depending on which generics are actively dispensing in your province. What the 65% number actually means — the floor reached only after three or more manufacturers are simultaneously on market.
What's not included — Wegovy patients (yet)
The April and May 2026 generic approvals reference Ozempic as the brand-name comparator and cover the Type 2 diabetes indication only. Wegovy, which uses the same semaglutide molecule at higher weekly doses (up to 2.4 mg) and is approved by Health Canada specifically for chronic weight management, has no generic equivalent yet.
The reason isn't patent protection — Novo Nordisk's Canadian patent on semaglutide lapsed in 2020, and data exclusivity for both Ozempic and Wegovy expired on January 4, 2026. The regulatory path for a generic Wegovy is open. The actual reason no generic exists yet is that no manufacturer has filed an Abbreviated New Drug Submission (ANDS) referencing Wegovy — demonstrating bioequivalence at the higher Wegovy doses and pursuing the weight-management indication is a separate regulatory exercise from the diabetes-indication filings that have just cleared. At least one manufacturer (PharmaTher) has announced it is targeting the full 0.25–2.4 mg dose range, suggesting Wegovy-equivalent generics are likely later in 2026 or in 2027.
If your prescription is for Ozempic (including off-label use for weight management), you'll be eligible to switch to generic semaglutide once your dispensing pharmacy stocks it. If your prescription is specifically for Wegovy, generic substitution is not currently available — there is no approved generic to substitute. Telehealth providers in Canada can confirm which brand your prescription is written for if you're unsure. Your pharmacist or prescriber can also confirm.
New approvals are clearing. Don't miss the next one.
Get notified when additional generic semaglutide products are approved and prices are listed in Canada.
Get notified when generic semaglutide becomes available in Canada
Expected Q3 2026 — be the first to know
What you'll receive
- Email notification when additional generic semaglutide prices are listed
- Price comparison across Canadian pharmacies — in your province
- No spam — one email when prices are live, unsubscribe any time